These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27231169)

  • 1. Efficacy of Postoperative Hormone Replacement Therapy on Prognosis of Patients with Serous Ovarian Carcinoma.
    Zhang YL; Chen JH; Lu W; Li BL; Zhu QY; Wan XP
    Chin Med J (Engl); 2016 Jun; 129(11):1316-21. PubMed ID: 27231169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
    BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China.
    Wen Y; Huang H; Huang H; Wu M; Shen K; Pan L
    Climacteric; 2013 Dec; 16(6):673-81. PubMed ID: 23710587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.
    Fader AN; Java J; Krivak TC; Bristow RE; Tergas AI; Bookman MA; Armstrong DK; Tanner EJ; Gershenson DM
    Gynecol Oncol; 2014 Mar; 132(3):560-5. PubMed ID: 24333362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction].
    Gasowska-Bodnar A; Bodnar L; Wcisło GB; Jerzak MM; Szczylik C; Baranowski W
    Ginekol Pol; 2008 Feb; 79(2):108-14. PubMed ID: 18510089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis.
    Li D; Ding CY; Qiu LH
    Gynecol Oncol; 2015 Nov; 139(2):355-62. PubMed ID: 26232517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer.
    May T; Stewart JM; Bernardini MQ; Ferguson SE; Laframboise S; Jiang H; Rosen B
    Int J Gynaecol Obstet; 2018 Feb; 140(2):247-252. PubMed ID: 29095487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
    Shah JS; Gard GB; Yang J; Maidens J; Valmadre S; Soon PS; Marsh DJ
    Gynecol Oncol; 2018 Jan; 148(1):181-188. PubMed ID: 29132874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma].
    Lin J; Du J; Zhang CY; Xie QT; Zhang B; Liu CR
    Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):655-60. PubMed ID: 21176529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortium.
    Melmer A; Fineder L; Lamina C; Kollerits B; Dieplinger B; Braicu I; Sehouli J; Cadron I; Vergote I; Mahner S; Zeimet AG; Castillo-Tong DC; Ebenbichler CF; Zeillinger R; Dieplinger H
    Gynecol Oncol; 2013 Jan; 128(1):38-43. PubMed ID: 23063758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
    Tate S; Hirai Y; Takeshima N; Hasumi K
    Gynecol Oncol; 2005 Jan; 96(1):143-9. PubMed ID: 15589593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
    Panici PB; Maggioni A; Hacker N; Landoni F; Ackermann S; Campagnutta E; Tamussino K; Winter R; Pellegrino A; Greggi S; Angioli R; Manci N; Scambia G; Dell'Anna T; Fossati R; Floriani I; Rossi RS; Grassi R; Favalli G; Raspagliesi F; Giannarelli D; Martella L; Mangioni C
    J Natl Cancer Inst; 2005 Apr; 97(8):560-6. PubMed ID: 15840878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
    Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
    Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.